Business Context and Reporting Period
This Form 8-K is filed by Gemphire Therapeutics Inc. (not Metavia Inc.) on August 9, 2019. The filing primarily addresses two events: the issuance of a press release regarding financial results for the second quarter ended June 30, 2019, and a notice from the Nasdaq Stock Market regarding the company's failure to meet the minimum bid price requirement for continued listing.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references a press release (Exhibit 99.1) containing the Q2 2019 financial results, but the data itself is not included in the provided text.
Material Changes and Listing Status
- Nasdaq Non-Compliance: On August 8, 2019, the company received notice that its common stock closing bid price had been below the $1.00 per share minimum requirement for 30 consecutive business days.
- Compliance Period: The company has 180 calendar days (until February 4, 2020) to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.
- Delisting Risk: Failure to regain compliance by the deadline may result in delisting, though the company may be eligible for a second 180-day compliance period if it meets other listing standards and effects a reverse stock split.
Outlook, Management Commentary, and Risks
Proposed Merger: Management believes the proposed merger with NeuroBo Pharmaceuticals, Inc., which includes a contemplated reverse stock split, will address the Nasdaq compliance issue. The company intends to file a registration statement on Form S-4 containing a proxy statement/prospectus.
Risks and Contingencies:
- Uncertainty regarding the timing and consummation of the merger with NeuroBo.
- Risk of failing to obtain stockholder approval for the merger.
- Potential inability to regain Nasdaq compliance or qualify for a second compliance period.
- Risk of delisting if the merger does not close or if the bid price deficiency is not cured.
- Operational risks related to managing expenses pending the merger closing.
Investor Verification Checklist
- Verify the specific Q2 2019 financial results in the press release (Exhibit 99.1) referenced in the filing.
- Monitor the daily closing bid price of GEMP stock to track progress toward the $1.00 threshold.
- Review the upcoming Form S-4 proxy statement for details on the NeuroBo merger terms and the reverse stock split ratio.
- Confirm the status of stockholder approval for the proposed merger.
- Assess the company's cash runway and ability to fund operations if the merger is delayed or fails.